PBAC's latest decision on Ramucirumab: Not recommended (2019). Considered for Treatment of patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy, in combination with paclitaxel.
PBAC outcome
Not recommended
Restricted
ICER (AUD/QALY)
$200k/QALY
Range: $105k/QALY–$200k/QALY
Submissions
2
first 2018
Submissions
2
2018 → 2019
Eligible population
Adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy, ECOG performance status 0 or 1, treated in combination with paclitaxel
Therapy area
Oncology
Line of therapy
Second-line
Evidence base
RCT
Primary endpoint
OS
Key trials
RAINBOW
Comparator
paclitaxel
Economic model
CUA
Why PBAC said no
Reasons cited in the latest PSD: unacceptably high ICER at $105,000-$200,000/QALY (PBAC considered acceptable range $40,000-$45,000/QALY), modest clinical benefit, significant toxicity
Submission history
Mar 2018: Recommended with restriction · Authority Required
Jul 2019: Not recommended · Restricted — ICER $200k/QALY